Ten-year outcome after combined modality therapy for inflammatory breast cancer.
about
Update on inflammatory breast cancerShort- and long-term cause-specific survival of patients with inflammatory breast cancer.Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancerInternational expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentAnoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestrationConcomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment.Demographic, clinical, pathological, molecular, treatment characteristics and outcomes of nonmetastatic inflammatory breast cancer in Morocco: 2007 and 2008.Inflammatory breast cancer: what are the treatment options?Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation.Biology and management of inflammatory breast cancer.Neoadjuvant therapy for breast cancer.Inflammatory breast cancer: the disease, the biology, the treatment.Overview of preoperative radiochemotherapy in breast cancer: past or future?The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study.
P2860
Q24797853-4EB66BA5-717B-4173-AD66-4BCAC074B001Q24817154-0B75C29A-0829-4460-95D8-D6A5A3007719Q34782298-8C6367BD-18BA-494A-A436-03E37CE749C8Q35017523-B9D12BB2-DD46-41FC-BEFD-29B8FE7784CAQ35829855-E73B28EC-0EC2-4437-A607-A8AFFB30D6ABQ36611240-484BCEAD-7CA5-4A0D-8209-6E2444B8F25DQ37165892-6DCBDBE5-A770-4C19-BFC9-4E54D7C4C611Q37501320-64C78B38-978F-4D0D-B202-91EEA25F969EQ37642758-64876B87-B24E-4800-95E6-52EA76222159Q37687112-0D5E55EB-6EEB-4D02-948E-3B90FD45E091Q37687382-A8379187-0AC5-41CF-9164-2509B80C6E7DQ37699134-9CCDD04D-D83F-48DA-ABC3-5FCC8FDB0C4EQ37801500-39EF5E99-A669-44ED-8893-D8FF60F4E0AAQ37903139-08D083EB-4AF6-45F3-B69F-7B9409AA51FEQ39339815-B31B3710-C7C6-4A8B-B51C-D0AF09044F76Q39962699-05E638D5-ECAB-4FCC-A769-0E2C3E0B75E1Q44158111-057000FE-C0EB-461D-9475-8A30E54C0961Q44211796-06523E0B-1918-4EDD-A7E9-7FD3931E9CD1Q52962361-59347F61-9195-4351-8BCD-B439CA48BC66Q54281598-75BF2895-B997-490E-99EA-9790E09BE355Q54283392-B9FF5ABB-2525-4D65-A67E-893E5854878AQ55405935-F390F363-F3AE-4152-85E4-C7E6F13C8517
P2860
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
@ast
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
@en
type
label
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
@ast
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
@en
prefLabel
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
@ast
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
@en
P2093
P1476
Ten-year outcome after combined modality therapy for inflammatory breast cancer
@en
P2093
Delray Schultz
Helaine Bertsch
John Glick
Lawrence J Solin
P304
P356
10.1016/S0360-3016(02)04201-3
P407
P577
2003-04-01T00:00:00Z